Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORK9
- Development stage
- Preclinical
- Lead developer
- Orikine Bio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
ORK9 is a preclinical-stage bi-specific cytokine developed by Orikine Bio using its proprietary Foldikine™ platform. Designed for oncology applications, ORK9 functions by reprogramming tumor-associated macrophages (TAMs) within the tumor microenvironment. By modulating these cells, the drug aims to shift the immune landscape from an immunosuppressive state to one that actively supports anti-tumor activity. As a Foldikine, ORK9 is a precision-engineered protein that combines multiple cytokine signaling activities into a single molecule to achieve therapeutic effects not possible with naturally occurring cytokines.
- Other names
- Foldikine
Beyond the preview
Go deeper on ORK9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORK9.